The ToGA trial demonstrated that a recombinant humanized monoclonal antibody targeting HER2 significantly prolonged overall survival in patients with HER2-positive GC.10) Given that HER2 positivity tends to be higher in GAED than in conventional GC, patients with GAED may be good candidates for anti-HER2 therapy.11–13) Additionally, previous studies have reported that surgical resection for GC with liver metastases can improve survival rates in select patients.14–17). This evidence concerns the gene ERBB2 and gastric cancer.